A system for controlled neuromodulation procedures is disclosed. A system for controlled micro ablation procedures is disclosed. Systems and methods for imaging, monitoring, stimulating, and/or ablating neurological structures coupled to one or more organs of the lower urinary tract (LUT) are disclosed. Such processes may be used to alter the hormonal secretions from one or more organs, to modulate the growth of an organ, alter the growth rate or rate of perineural invasion of a tumor, or the like. In particular such processes may be used to slow, halt and/or reverse the growth of a prostate gland or a prostate tumor.

A system is provided with an insulin delivery device configured to deliver insulin to a user of the system and a computer-based control unit associated with the insulin delivery device. The computer-based control unit includes a user interface and a computer-based processor. The computer-based processor is configured to calculate a relative insulin on board value for a specific time by calculating a first value that represents a reference insulin on board value at the specific time, calculating a second value that represents an automated insulin on board value at the specific time, and subtracting one of the first and second values from the other. The automated insulin on board value represents at least one insulin delivery automatically specified by the computer-based control unit. Methods of use are also disclosed.

A method of dispensing fluid includes three processes. A first one of these processes includes pumping fluid into a resilient variable-volume dispensing chamber. The dispensing chamber is in series with a normally present finite fluid impedance and an output. The impedance is sufficient so as to cause expansion of the dispensing chamber as it receives pumped fluid even while some fluid flows through the output. Another one of these processes includes repeatedly measuring a parameter related to volume of the dispensing chamber over time. A third one of these processes includes controlling the pumping of fluid based on repeated measurements of the parameter to produce a desired fluid flow through the output. A corresponding system for dispensing fluid implements these processes.

A medical device comprising an infusion device comprising a fluid reservoir to contain a therapeutic fluid and a transcutaneous access tool fluidly coupled to the fluid reservoir, the transcutaneous access tool configured to deliver the therapeutic fluid subcutaneously to a patient; wherein the infusion device operates in a stand-by mode prior to the therapeutic fluid being introduced into the fluid reservoir; wherein the infusion device operates to deploy the transcutaneous access tool within a predetermined deployment time period upon filling the fluid reservoir to a predetermined fill level with the therapeutic fluid.

A continuous glucose monitoring system may employ complex redundancy to take operational advantage of disparate characteristics of two or more dissimilar, or non-identical, sensors, including, e.g., characteristics relating to hydration, stabilization, and durability of such sensors. Fusion algorithms, Electrochemical Impedance Spectroscopy (EIS), and advanced Application Specific Integrated Circuits (ASICs) may be used to implement use of such redundant glucose sensors, devices, and sensor systems in such a way as to bridge the gaps between fast start-up, sensor longevity, and accuracy of calibration-free algorithms. Systems, devices, and algorithms are described for achieving a long-wear and reliable sensor which also minimizes, or eliminates, the need for BG calibration, thereby providing a calibration-free, or near calibration-free, sensor.

Techniques related to advance diagnosis of operating mode viability are disclosed. The techniques may involve obtaining status information pertaining to operation of a fluid delivery device. The status information may include at least one of a group comprising recent sensor measurement data, sensor calibration data, blood glucose reference measurement data, fluid delivery data, a current battery level of the fluid delivery device, and a current amount of fluid remaining in the fluid delivery device. The techniques may further involve determining, based on the status information, viability of transitioning to a destination operating mode of the fluid delivery device. Additionally, the techniques may involve causing generation of one or more user notifications of recommended remedial actions to improve the viability of transitioning to the destination operating mode when transitioning into the destination operating mode is determined not to be viable.

This application describes a method and device for safely, effectively, perfusing distal to occluded arteries, based on diagnostic information from the catheter-perfusion-system based on sensors, effectors, controllers and algorithms included, with particular attention to the specific characteristics of the tissue and the fluid. Key actionable physiological values for the tissue can be calculated and derived. They include the auto-regulatory curve, with Upper and Lower limits of Auto regulation, vascular reserve, and collateral flow reserve and as auto-regulation exhaustion.

An injection system is described that receives, from one or more sensors, a first group of one or more signals indicating a current volume of injection fluid dispensed from a fluid reservoir at a first time. The injection system determines, based on the first group of one or more signals, that a difference between a dispensed volume limit and the current volume of the injection fluid dispensed from the fluid reservoir at the first time is less than a necessary volume of fluid required to complete both a systolic injection phase and a diastolic injection phase. The injection system further, responsive to determining that the difference is less than the necessary volume of fluid required to complete both the systolic injection phase and the diastolic injection phase, controls the injection system to refrain from performing each of the systolic injection phase and the diastolic injection phase.

A system for controlled neuromodulation procedures is disclosed. A system for controlled micro ablation procedures is disclosed. Systems and methods for imaging, monitoring, stimulating, and/or ablating neurological structures coupled to one or more organs of the lower urinary tract (LUT) are disclosed. Such processes may be used to alter the hormonal secretions from one or more organs, to modulate the growth of an organ, alter the growth rate or rate of perineural invasion of a tumor, or the like. In particular such processes may be used to slow, halt and/or reverse the growth of a prostate gland or a prostate tumor.

Provided is a liquid medication control injection device including a blood glucose measuring unit configured to measure blood glucose of target of injection at least a plurality of times, sequentially, a first liquid medication injection unit configured to inject a first liquid medication containing a component for controlling a decrease in blood glucose of the target of injection to the target of injection, and a second liquid medication injection unit configured to inject a second liquid medication containing a component for controlling an increase in blood glucose of the target of injection, wherein the component of the second liquid medication is different from that of the first liquid medication.